Pamidronate associated with high incremental costs per adverse event avoided in patients with metastatic breast cancer
Martine ExtermannVolume:
1
Year:
2000
Language:
english
Pages:
2
DOI:
10.1054/ebon.2000.0033
File:
PDF, 167 KB
english, 2000